Lung Cancer: Biomarkers, Tyrosine Kinase Inhibitors and Monoclonal Antibodies
Abstract
Lung cancer is the most contributor of cancer cause death in the world. Lung cancer is related to cigarette consumption and genetic factor. Nicotine derived nitrosamine ketone is the most important inducer of lung cancer associated with DNA Mutations resulting in the activation of Kirsten rat sarcoma viral (KRAS) oncogenes. DNA Mutation in Lung cancer is mostly presence by epidermal growth factor receptor (EGFR) mutations. There were seven potential biomarkers to detect early lung cancer, whereas carcinoembryonic antigen (CEA), neuron specific enolase (NSE), cytokeratin-19 fragments (CYFRA 21-1), alpha-fetoprotein (AFP), cancer antigen 125 (CA-125), CA-199 and ferritin. The use of biomarkers in combination can improve the accuracy in diagnosing lung cancer. Other biomarkers include KRAS mutations, B-type Raf kinase (BRAF) mutation, mesenchymal-epithelial transition factor (MET) amplification and Excision repair cross-complementing group 1 (ERCC1) can be used to see whether there are any genetic mutations that lead to lung cancer. Treatment of lung cancer with chemotherapy can be done using tyrosine kinase inhibitors and monoclonal antibodies.
Keywords: lung cancer, DNA mutation, EGFR, KRAS, BRAF, MET, tyrosine kinase
Full Text:
PDFReferences
Todaro GJ, DeLarco JE, Cohen S. Transformation by Murine and Feline Sarcoma Viruses Specifically Blocks Binding of Epidermal Growth Factor to Cells. Nature 1976; 264: 26-31. CrossRef
Herbst RS, Heymach JV, Lippman SM. Lung Cancer. N Engl J Med. 2008; 359: 1367-80. CrossRef
Yarden Y, Sliwkowski MX. Untangling The ErbB Signaling Network. Nat Rev Mol Cell Biol. 2001; 2(2): 127-37. CrossRef
Schlessinger J. Cell Signaling by Receptor Tyrosine Kinases. Cell. 2000; 103(2): 211-25. CrossRef
Hendarmin L, Sandra F, Nakao Y, Ohishi M, Nakamura N. TNFalpha played a role in induction of Akt and MAPK signals in ameloblastoma. Oral Oncol. 2005; 41(4): 375-82. CrossRef
Sandra F, Hendarmin L, Nakao Y, Nakamura N, Nakamura S. Inhibition of Akt and MAPK pathways elevated potential of TNFalpha in inducing apoptosis in ameloblastoma. Oral Oncol. 2006; 42(1): 39-45. CrossRef
Sandra F, Matsuki NA, Takeuchi H, Ikebe T, Kanematsu T, Ohishi M, Hirata M. TNF inhibited the apoptosis by activation of Akt serine/threonine kinase in the human head and neck squamous cell carcinoma. Cell Signal. 2002; 14(9): 771-8. CrossRef
Hanahan D, Weinberg RA. The Hallmarks of Cancer. Cell. 2000; 100(1): 57-70. CrossRef
Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J. An Allosteric Mechanism for Activation of The Kinase Domain of Epidermal Growth Factor Receptor. Cell. 2006; 125(6): 1137-49. CrossRef
Okabe T, Okamoto I, Tamura K, Terashima M, Yoshida T, Satoh T, et al. Differential Constitutive Activation of The Epidermal Growth Factor Receptor in Non-Small Cell Lung Cancer Cells Bearing EGFR Gene Mutation and Amplification. Cancer Res. 2007; 67(5): 2046-53. CrossRef
Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, et al. EGFR Mutations in Non-Small-Cell Lung Cancer: Analysis of A Large Series of Cases and Development of A Rapid and Sensitive Method for Diagnostic Screening with Potential Implications on Pharmacologic Treatment. J Clin Oncol. 2005; 23(4): 857-65. CrossRef
Hammerman PS, Janne PA, Johnson BE. Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. Clin Cancer Res. 2009; 15(24): 7502-9. CrossRef
West H, Lilenbaum R, Harpole D, Wozniak A, Sequist L. Molecular Analysis-Based Treatment Strategies for The Management of Non-Small Cell Lung Cancer. J Thorac Oncol. 2009; 4 (9 Suppl 2): S1029-39; quiz S1041-2. CrossRef
Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF Receptor Gene Mutations are Common in Lung Cancers from ‘Never Smokers’ and are Associated with Sensitivity of Tumors to Gefitinib and Erlotinib. Proc Natl Acad Sci USA. 2004; 101(36): 13306-11. CrossRef
Knop CS. Lung cancer. In: Yarbro CH, Frogge MH, Goodman M, editors. Cancer Nursing: Principles and Practice. 6th ed. Boston: Jones & Bartlett; 2005. p.1379-1413. Link
Van Cleave JH, Cooley ME. Lung cancer. In: Varricchio CG, editor. A Cancer Sourcebook for Nurses. 8th ed. Sudbury: Jones & Bartlett; 2004. p.215-29. Link
Chen YB, Mu CY, Huang JA. Clinical Significance of Programmed Death-1 Ligand-1 Expression in Patients with Nonsmall Cell Lung Cancer: A 5-Year-Follow-Up Study. Tumori. 2012; 98(6): 751-5. CrossRef
D’Amato TA, Landreneau RJ, McKenna RJ, Santos RS, Parker RJ. Prevalence of In Vitro Extreme Chemotherapy Resistance in Resected Nonsmall-Cell Lung Cancer. Ann Thorac Surg. 2006; 81(2): 440-7. CrossRef
Eckardt JR, Bentsion DL, Lipatov ON, Polyakov IS, Mackintosh FR, Karlin DA, et al. Phase II Study of Picoplatin as Second-line Therapy for Patients with Small Cell Lung Cancer. J Clin Oncol. 2009; 27(12): 2046-51. CrossRef
Mauer AM, Cohen EE, Ma PC, Kozloff MF, Schwartzberg L, Coates AI, et al. A Phase II Study of ABT-751 in Patients with Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2008; 3(6): 631-6. CrossRef
Verrils NM, Flemming CL, Liu M, Ivery MT, Cobon GS, Norris MD, et al. Microtubule Alterations and Mutations Induced by Desoxyepothilone B: Implications for Drug-Target Interaction. Chem Biol. 2003; 10(7): 597-607. CrossRef
Magnani N, Ortuso F, Soro S, Alcaro S, Tramontano A, Botta M. The βI/βIII-tubulin Isoforms and Their Complexes with Antimitotic Agents. FEBS J. 2006; 273(14): 3301-10. CrossRef
Jordan MA, Miller H, Ray A, Banerjee A, Manna T, Ni L, et al. The Pat-21 breast cancer model derived from a patient with primary Taxol resistance recapitulates the phenotype of its origin has altered β-tubulin expression and is sensitive to ixabepilone. Presented at the 97th AACR Annual Meeting. Washington, District of Colombia, April 1-5; 2006 [abstract LB-280]. Link
Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, et al. Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative Recurrence. J Clin Oncol. 2005; 23(11): 2513-20. CrossRef
Cheng L, Zhang S, Alexander R, Yao Y, MacLennan GT, Pan CX, et al. The Landscape of EGFR Pathways and Personalized Management of Nonsmall-Cell Lung Cancer. Future Oncol. 2011; 7(4): 519-41. CrossRef
Keedy VL, Temin S, Somerfield MR, Beasley MB, Johnson DH, McShane LM, et al. American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non- Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy. J Clin Oncol. 2011; 29(15): 2121-7. CrossRef
Cataldo VD, Gibbons DL, Pérez-Soler R, Quintás-Cardama A. Treatment of Non-Small-Cell Lung Cancer with Erlotinib or Gefitinib. N Engl J Med. 2011; 364(10): 947-55. CrossRef
Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG, Jakobovits A. Eradication of Established Tumors by a Fully Human Monoclonal Antibody to the Epidermal Growth Factor Receptor without Concomitant Chemotherapy. Cancer Res. 1999; 59(6): 1236-43. Link
Brahmer J, Karen LR, Baas P, Crino L, Eberhardt WEE, Poddubskaya E, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17): 123-35. CrossRef
Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, et al. Pembrolizumab versus Investigator-Choice Chemotherapy for Ipilimumab-Refractory Melanoma (KEYNOTE-002): A Randomised, Controlled, Phase 2 Trial. Lancet Oncol. 2015; 16: 908-18. CrossRef
Dela Cruz CS, Tanoue LT, Matthay RA. Lung Cancer: Epidemiology, Etiology, and Prevention. Clin Chest Med. 2011; 32(4): 605-44. CrossRef
Rades D, Käsmann L, Schild SE, Janssen SA. Survival Score for Patients Receiving Palliative Irradiation for Locally Advanced Lung Cancer. Clin Lung Cancer. 2016; 17(6): 558-62. CrossRef
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375(19): 1823-33. CrossRef
Li X, Asmitananda T, Gao L, Gai D, Song Z, Zhang Y, et al. Biomarkers in the Lung Cancer Diagnosis: A Clinical Perspective. Neoplasma. 2012; 59(5): 500-7. CrossRef
Meiliana A, Dewi NM, Wijaya A. Cancer Immunotherapy: A Review. Indones Biomed J. 2016; 8: 1-20. CrossRef
Chae YK, Pan A, Davis AA, Raparia K, Mohindra NA, Matsangou M, et al. Biomarkers For PD-1/PD-L1 Blockade Therapy in Non-Small-Cell Lung Cancer: Is PD-L1 Expression A Good Marker For Patient Selection?. Clin Lung Cancer. 2016; 17(5): 350-61. CrossRef
Meiliana A, Dewi NM, Wijaya A. Personalized Medicine: The Future of Health Care. Indones Biomed J. 2016; 8: 127-46. CrossRef
Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma. N Engl J Med. 2009; 361: 947-57. CrossRef
Jackman DM, Miller VA, Cioffredi LA, Yeap BY, Jänne PA, Riely GJ, et al. Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non-Small Cell Lung Cancer Patients: Results of An Online Tumor Registry of Clinical Trials. Clin Cancer Res. 2009; 15(16): 5267-73. CrossRef
Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, et al. KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib. PLoS Med. 2005; 2(1): e17. CrossRef
Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, et al. High-throughput Oncogene Mutation Profiling in Human Cancer. Nat Genet. 2007; 39(3): 347-51. CrossRef
Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, et al. Assessment of Somatic k-RAS Mutations as A Mechanism Associated with Resistance to EGFR-Targeted Agents: A Systematic Review and Meta-Analysis of Studies in Advanced Non-Small-Cell Lung Cancer and Metastatic Colorectal Cancer. Lancet Oncol. 2008; 9(10): 962-72. CrossRef
Mao C, Qiu LX, Liao RY, Du FB, Ding H, Yang WC, et al. KRAS Mutations and Resistance to EGFR-TKIs Treatment in Patients with Non-Small Cell Lung Cancer: A Meta-Analysis of 22 Studies. Lung Cancer. 2011; 69(3): 272-8. CrossRef
Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, et al. Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib. J Clin Oncol. 2005; 23(25): 5900-9. CrossRef
De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA Mutations on The Efficacy of Cetuximab Plus Chemotherapy in Chemotherapy-Refractory Metastatic Colorectal Cancer: A Retrospective Consortium Analysis. Lancet Oncol. 2010; 11(8): 753-62. CrossRef
Vakiani E, Solit DB. KRAS and BRAF: Drug Targets and Predictive Biomarkers. J Pathol. 2011; 223(2): 219-29. CrossRef
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of The BRAF Gene in Human Cancer. Nature. 2002; 417: 949-54. CrossRef
Schmid K, Oehl N, Wrba F, Pirker R, Pirker C, Filipits M. EGFR/KRAS/BRAF Mutations in Primary Lung Adenocarcinomas and Corresponding Locoregional Lymph Node Metastases. Clin Cancer Res. 2009; 15(14): 4554-60. CrossRef
Ladanyi M, Pao W. Lung Adenocarcinoma: Guiding EGFR-Targeted Therapy and Beyond. Mod Pathol. 2008; 21(Suppl 2): S16-S22. CrossRef
Seki T, Hagiya M, Shimonishi M, Nakamura T, Shimizu S. Organization of The Human Hepatocyte Growth Factor-Encoding Gene. Gene 1991; 102(2): 213-9. CrossRef
Nguyen KS, Kobayashi S, Costa DB. Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway. Clin Lung Cancer. 2009; 10(4): 281-9. CrossRef
Beau-Faller M, Ruppert AM, Voegeli AC, Neuville A, Meyer N, Guerin E, et al. MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort. J Thorac Oncol. 2008; 3(4): 331-9. CrossRef
Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling. Science. 2007; 316(5827): 1039-43. CrossRef
Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer. Clin Cancer Res. 2009; 15(7): 2207-14. CrossRef
Gandara DR, Grimminger P, Mack PC, Lara PN Jr, Li T, Danenberg PV, et al. Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer. J Thorac Oncol. 2010; 5(12): 1933-8. CrossRef
Gomez-Roca C, Raynaud CM, Penault-Llorca F, Mercier O, Commo F, Morat L, et al. Differential Expression of Biomarkers in Primary Non-small Cell Lung Cancer and Metastatic Sites. J Thorac Oncol. 2009; 4(10): 1212-20. CrossRef
Cheng L, Alexander RE, Maclennan GT, Cummings OW, Montironi R, Lopez-Beltran A, et al. Molecular Pathology of Lung Cancer: Key to Personalized Medicine. Mod Pathol. 2012; 25(3): 347-69. CrossRef
DOI: https://doi.org/10.21705/mcbs.v1i2.10
Copyright (c) 2017 Cell and BioPharmaceutical Institute
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
Cell and BioPharmaceutical Institute
